Bhaskar Chaudhuri
Known title: DirectorCIK: 0001458643
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
Transaction History
| TARS | ▲ Buy | Option Exercise | 2,954 | — | 6/12/2026 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/13/2025 | View on chart |
| ARQT | ▲ Buy | Grant | 7,609 | $0 | 6/12/2025 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/24/2024 | View on chart |
| ARQT | ▲ Buy | Grant | 10,139 | $0 | 6/14/2024 | View on chart |
| TARS | ▲ Buy | Option Exercise | 2,000 | — | 6/16/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 4,375 | $0 | 5/31/2023 | View on chart |
| ARQT | ▲ Buy | Grant | 4,312 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals
The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals. The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.